厄贝沙坦氢氯噻嗪复方制剂治疗原发性高血压有效性及安全性的Meta分析被引量：6

Meta-analysis on effectiveness and safety of irbesarten/hydrochlorothiazide combination therapy in treatment of essential hypertension

在线阅读下载PDF

导出

摘要目的:利用Meta分析方法探讨厄贝沙坦氢氯噻嗪复方制剂治疗原发性高血压的有效性及安全性,为其临床应用提供依据。方法:计算机检索Cochrane图书馆临床对照试验资料库(2010年第03期)、Ovid-medline全文数据库(1966-2010.09)、PubMed数据库(1948-2010.09)、EMBASE数据库(1966-2010.09)、中国学术文献总库(CNKI)(1979-2010.09)、万方数字化期刊库(1981-2010.09)及维普数据库(VIP)(1989-2010.09),手工检索相关文献,按纳入与排除标准选择试验、评价质量,提取资料,并用RevMan 4.2软件对数据进行Meta分析。结果:共初检出516篇文献,经筛选最终纳入5篇6项关于厄贝沙坦氢氯噻嗪治疗原发性高血压的随机双盲对照研究。有效性:χ2=7.50,df=5,P=0.19,Z=7.23(P<0.00001),合并OR=2.26,95%CI[1.81,2.82];安全性:χ2=7.82,df=5,P=0.17,Z=1.11(P=0.27),合并OR=0.87,95%CI[0.68,1.11]。结论:厄贝沙坦氢氯噻嗪复方制剂治疗原发性高血压与对照组比较具有较高的有效性及相似的安全性。 Objective To approach the effectiveness and safety of irbesarten/hydrochlorothiazide combination therapy in treating essential hypertension with Meta-analysis and provide basis for their application in clinic.Methods Computer search was performed using the Cochrane Central Register of Controlled Trials（Issue3,2010）,Ovid-medline（1966 to September 2010）,PubMed（1948-2010.09）,EMBASE（1966 to September 2010）,CNKI（1979 to September 2010）,WanFang（1981-2010.09）,VIP（1989-2010.09）,the randomized controlled trials（RCTs） were collected,then the retrieved studies according to predefined inclusion and exclusion criteria were screened,the quality of included studies was evaluated and RevMan 4.2 software was used for Meta analysis.Results A total of 516 articles were found and 5 of which were finally included.Effectiveness：χ2=7.50,df=5,P=0.19,Z=7.23（P0.00001）,OR=2.26,95%CI[1.81,2.82];Safety：χ2=7.82,df=5,P=0.17,Z=1.11（P=0.27）,OR=0.87,95%CI[0.68,1.11].Conclusion Irbesarten/hydrochlorothiazide combination therapy is more effective than control group in treating essential hypertension and there is no significant difference in safety between them.

作者吴海帝徐国良秦玲

机构地区吉林大学第一医院二部心内科

出处《吉林大学学报（医学版）》 CAS CSCD 北大核心 2011年第3期517-522,共6页 Journal of Jilin University：Medicine Edition

基金吉林省科技厅科研基金资助课题(200905138)

关键词厄贝沙坦氢氯噻嗪原发性高血压 META分析 irbesarten hydrochlorothiazide essential hypertension Mata-analysis

分类号 R544.1 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献16

1陆再英,钟南山.内科学[M].北京:人民卫生出版社,2007.26.
2刘力生,王文,姚崇华.中国高血压防治指南(2009年基层版)[J].中华高血压杂志,2010,18(1):11-30. 被引量：861
3Law MR, Morris JK, Wald HJ, et al. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiologieal studies[J].BMJ, 2009, 338 (10): 1665 -1668.
4Wald DS, Law M, Morris JK, el al. Combination therapy versus monotherapy in reducing blood pressure: meta analysis on 11 000 participants from 42 trials [J]. Am J Med, 2009, 122 (3): 290-300.
5中国高血压防治指南[J].高血压杂志,2000,8(2):103-112. 被引量：172
6WHO-ISH Hypertension Guidelines Committee. 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension [J].J Hypertens, 1999, 17 (2): 151-183.
7刘国仗,胡大一,陶萍,诸骏仁,郭林妮,郭静萱,游凯.心血管药物临床试验评价方法的建议[J].中华心血管病杂志,1998,26(1):5-11. 被引量：1440
8Sackett DL, Clarke M, Oxman AD, et al. Cochrane Reviewers, Handbook 4.2, In Renew Manager [ M]. Oxford: The Cochrane Collaboration, 2002: 13-36.
9Jadad AR, Moore A, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? [J]. Control Clin Trials, 1996, 17 (1) : 1- 12.
10Joel M, Stanley S, Suzanne O, et al. Efficacy and safety of Irbesartan/HCTZ combination theraphy as initial treatment for rapid control of severe hypertension [J]. J Clin Hypertens,2006, 8 (12): 850-857.